 |
9 Diseases |  |
0 Trials |
|
0 Trials |  |
92 News |  |
| 12» |
- || gp96-Ig vaccine / Sylvester Comprehensive Cancer Center, viagenpumatucel-L (HS-110) / NightHawk Biosci
Review, Journal: "All for One and One for All": The Secreted Heat Shock Protein gp96-Ig Based Vaccines. (Pubmed Central) - Jan 15, 2024
In this review, we will highlight three major principles of the gp96-Ig vaccine strategy: (1) presentation of pathogenic antigens to T cells (specificity); (2) activation of innate immune responses (adjuvanticity); (3) priming of T cells to home to the epithelial compartments (mucosal immunity). In summary, we provide a paradigm for a vaccine approach that can be rapidly engineered and customized for any future pathogens that require induction of effective tissue-resident memory responses in epithelial tissues.
- || viagenpumatucel-L (HS-110) / NightHawk Biosci
Enrollment closed, Trial completion date, Combination therapy: DURGA: A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov) - Oct 5, 2022
P1b/2, N=121, Active, not recruiting, Sponsor: Heat Biologics
In summary, we provide a paradigm for a vaccine approach that can be rapidly engineered and customized for any future pathogens that require induction of effective tissue-resident memory responses in epithelial tissues. Completed --> Active, not recruiting | Trial completion date: Aug 2022 --> Nov 2022
- || HS-130 / NightHawk Biosci, viagenpumatucel-L (HS-110) / NightHawk Biosci
Trial completion, Combination therapy: A Phase 1 Study of HS130 in Combination With Viagenpumatucel-L (HS110) in Patients With Solid Tumors (clinicaltrials.gov) - Aug 29, 2022
P1, N=15, Completed, Sponsor: Heat Biologics
Completed --> Active, not recruiting | Trial completion date: Aug 2022 --> Nov 2022 Active, not recruiting --> Completed
- ||| viagenpumatucel-L (HS-110) / NightHawk Biosci
Trial completion, Combination therapy: DURGA: A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov) - Aug 29, 2022
P1b/2, N=121, Completed, Sponsor: Heat Biologics
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | gp96-Ig vaccine / Sylvester Comprehensive Cancer Center, viagenpumatucel-L (HS-110) / Heat Biologics
Journal: Secreted heat shock protein gp96-Ig and OX40L-Fc combination vaccine enhances SARS-CoV-2 Spike (S) protein-specific B and T cell immune responses. (Pubmed Central) - Aug 10, 2022
Thus, a cell-based gp96-Ig vaccine/OX40-L fusion protein regimen provides encouraging translational data that this vaccine platform induces pathogen-specific CD8+, CD4+ T and B cell responses, and may cohesively work as a booster for FDA-approved vaccines. Our vaccine platform can be rapidly engineered and customized based on other current and future pathogen sequences.
- || viagenpumatucel-L (HS-110) / NightHawk Biosci
Trial primary completion date, Combination therapy: DURGA: A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov) - Sep 28, 2021
P1b/2, N=121, Active, not recruiting, Sponsor: Heat Biologics
Our vaccine platform can be rapidly engineered and customized based on other current and future pathogen sequences. Trial primary completion date: Aug 2021 --> May 2021
- || HS-130 / NightHawk Biosci, viagenpumatucel-L (HS-110) / NightHawk Biosci
Enrollment closed, Enrollment change, Combination therapy: A Phase 1 Study of HS130 in Combination With Viagenpumatucel-L (HS110) in Patients With Solid Tumors (clinicaltrials.gov) - Sep 24, 2021
P1, N=15, Active, not recruiting, Sponsor: Heat Biologics
Trial primary completion date: Aug 2021 --> May 2021 Recruiting --> Active, not recruiting | N=30 --> 15
- ||| viagenpumatucel-L (HS-110) / Heat Biologics
$HTBX HS-110 Presentation at ASCO #ASCO21 #antibodies - https://t.co/ubHKAkMNJ8 (Twitter) - Jun 17, 2021
- |||| viagenpumatucel-L (HS-110) / Heat Biologics
$HTBX HS-110 Presentation at ASCO #ASCO21 #CellTherapy - https://t.co/KcWGxlwmxY (Twitter) - Jun 8, 2021
- HS-130 / Heat Biologics, viagenpumatucel-L (HS-110) / Heat Biologics, PTX-35 / Heat Biologics
[VIRTUAL] Heat Biologics () - May 31, 2021 - Abstract #BIO2021BIO_366;
The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in its Phase 2 trial, and a COVID-19 vaccine program in preclinical development. In addition, Heat Biologics is also developing a pipeline of proprietary immunomodulatory antibodies and cell-based therapies, including PTX-35 and HS-130 in Phase 1 clinical trials.
- gp96-Ig vaccine / Sylvester Comprehensive Cancer Center, viagenpumatucel-L (HS-110) / Heat Biologics
[VIRTUAL] Development of a gp96-Ig vaccine for COVID-19 () - May 19, 2021 - Abstract #IMMUNOLOGY2021IMMUNOLOGY_1482;
We showed that our vaccine platform effectively stimulates a robust cellular immune response against protein S. Moreover, we confirmed that gp96-Ig, secreted from allogeneic cells expressing full-length protein S, generates powerful, protein S polyepitope-specific CD4+ and CD8+ T cell responses in both lung interstitium and airways. These findings were further strengthened by the observation that protein-S -specific CD8+ T cells were induced in human leukocyte antigen (HLA)-A2-02-01 transgenic mice thus providing encouraging translational data that the vaccine is likely to work in humans, in the context of SARS-CoV-2 antigen presentation.
- viagenpumatucel-L (HS-110) / Heat Biologics, Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] Interim results of viagenpumatucel-L (HS-110) plus nivolumab in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC) in two treatment settings. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1075;
P1b/2
In previously treated pts with advanced NSCLC, we observed (1) significantly longer PFS and OS in ISR+ pts in both CPI naïve and CPI progressor cohorts; (2) significantly longer OS in PD-L1+ patients in the CPI naïve cohort; and (3) a trend of improved OS in bTMB-L pts in the CPI progressor cohort . Further clinical evaluation of HS-110 is warranted in both CPI naïve and CPI progressor NSCLC patients.
- || viagenpumatucel-L (HS-110) / NightHawk Biosci
Trial completion date, Trial primary completion date, Combination therapy, PD(L)-1 Biomarker: DURGA: A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jan 22, 2021
P1b/2, N=121, Active, not recruiting, Sponsor: Heat Biologics
Further clinical evaluation of HS-110 is warranted in both CPI naïve and CPI progressor NSCLC patients. Trial completion date: Dec 2021 --> Aug 2022 | Trial primary completion date: Dec 2020 --> Aug 2021
- | HS-130 / NightHawk Biosci, viagenpumatucel-L (HS-110) / NightHawk Biosci
Trial completion date, Trial primary completion date, Combination therapy: A Phase 1 Study of HS130 in Combination With Viagenpumatucel-L (HS110) in Patients With Solid Tumors (clinicaltrials.gov) - Jan 22, 2021
P1, N=30, Recruiting, Sponsor: Heat Biologics
Trial completion date: Dec 2021 --> Aug 2022 | Trial primary completion date: Dec 2020 --> Aug 2021 Trial completion date: May 2021 --> Nov 2021 | Trial primary completion date: Nov 2020 --> Jun 2021
- || HS-130 / Heat Biologics, viagenpumatucel-L (HS-110) / Heat Biologics, PTX-35 / Heat Biologics
P1 data, P2 data: ‣ Complete HS-130 Phase I trial – 1Q:21 ‣ Complete PTX-35 Phase I trial – 1Q:21 ‣ End of Phase II meeting for HS-110 – 1H:21 (Twitter) - Jan 14, 2021
- | viagenpumatucel-L (HS-110) / Heat Biologics
HS-110 results. Stop with the tweets. Stop with the fluff. We want results!!!! (Twitter) - Jan 12, 2021
- viagenpumatucel-L (HS-110) / Heat Biologics, Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] Impact of adding viagenpumatucel-L to nivolumab in non-small cell lung cancer (NSCLC) patients with low levels of tumour infiltrating lymphocytes (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_2170;
Legal entity responsible for the study: Heat Biologics, Inc. Funding: Heat Biologics, Inc.
- PTX-35 / Heat Biologics
A novel TNFRSF25 agonist, PTX35, synergizes with Gp96-Ig/OX40L-Ig to enhance effector and memory anti-tumor CD8+ T cell responses and delay tumor growth (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_698;
We also assessed if PD-1 antagonist therapies further amplified our responses and found that checkpoint inhibition (CPI) synergizes effectively with PTX-35 and mHS-110. Therefore, the combinations of these treatments along with CPI may translate into an efficacious approach to treating human cancers.
- viagenpumatucel-L (HS-110) / Heat Biologics, Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] Tumor antigen expression and survival of patients with previously treated advanced non-small cell lung cancer (NSCLC) receiving viagenpumatucel-L (HS-110) plus nivolumab. (Poster Board 312) - Apr 29, 2020 - Abstract #ASCO2020ASCO_2404;
P1b/2
OS was improved in pts whose tumors express ≥ 8 shared antigens with HS110, as well as in those who specifically expressed ZNF492. Further exploration of antigen expression as a predictor for treatment outcome with HS110 plus nivolumab is ongoing.
- || viagenpumatucel-L (HS-110) / NightHawk Biosci
Trial primary completion date, Combination therapy, PD(L)-1 Biomarker: DURGA: A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov) - Apr 27, 2020
P1b/2, N=121, Active, not recruiting, Sponsor: Heat Biologics
Further exploration of antigen expression as a predictor for treatment outcome with HS110 plus nivolumab is ongoing. Trial primary completion date: Dec 2019 --> Dec 2020
- gp96-Ig vaccine / Sylvester Comprehensive Cancer Center, viagenpumatucel-L (HS-110) / Heat Biologics
Secreted heat shock protein gp96-Ig vaccine induces malaria specific intrahepatic CD8 T cell responses (Board Number: P1266) - Apr 25, 2020 - Abstract #IMMUNOLOGY2020IMMUNOLOGY_843;
Also, we found an increased frequency of intrahepatic CD8+ T cells secreting IL-2, which is relevant for maintenance of effective memory responses. Our findings are strongly supportive of a novel gp96-Ig-based malaria vaccine as a unique systemic and liver-homing, liver-stage antigen-specific CD8+ cytotoxic T lymphocyte (CTL) vaccine strategy.
- ||||| viagenpumatucel-L (HS-110) / NightHawk Biosci
Trial termination, Combination therapy, Metastases: A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov) - Feb 5, 2020
P2, N=66, Terminated, Sponsor: Heat Biologics
Our findings are strongly supportive of a novel gp96-Ig-based malaria vaccine as a unique systemic and liver-homing, liver-stage antigen-specific CD8+ cytotoxic T lymphocyte (CTL) vaccine strategy. Completed --> Terminated; Sponsor Decision; strategic - based on changing treatment landscape
- | HS-130 / NightHawk Biosci, viagenpumatucel-L (HS-110) / NightHawk Biosci
Enrollment open, Combination therapy: A Phase 1 Study of HS130 in Combination With Viagenpumatucel-L (HS110) in Patients With Solid Tumors (clinicaltrials.gov) - Oct 21, 2019
P1, N=30, Recruiting, Sponsor: Heat Biologics
Completed --> Terminated; Sponsor Decision; strategic - based on changing treatment landscape Not yet recruiting --> Recruiting
- | HS-130 / NightHawk Biosci, viagenpumatucel-L (HS-110) / NightHawk Biosci
New P1 trial, Combination therapy: A Phase 1 Study of HS130 in Combination With Viagenpumatucel-L (HS110) in Patients With Solid Tumors (clinicaltrials.gov) - Oct 6, 2019
P1, N=30, Not yet recruiting, Sponsor: Heat Biologics
- viagenpumatucel-L (HS-110) / Heat Biologics
Preclinical Development of a Novel, Allogeneic, OX40L-Secreting, Therapeutic Cancer Vaccine for use in Combination with a gp96-Secreting Vaccine for Solid Tumors (Prince George's Exhibition Halls AB) - Oct 2, 2019 - Abstract #SITC2019SITC_1164;
Best dose group combination mHS-110/gp96-Ig to mHS-130/OX40L-Ig was at a ratio of 1 to 1.3, at a dose rate of 339 ng/10^6 cells/24 hrs of gp96-Ig to 441 ng/10^6 cells/24 hrs of OX40L-Ig, with a NOEL of 38 ng gp96-Ig to 50 ng OX40L, a MABEL of 113 ng gp96-Ig to 147 ng OX40L-Ig. These results support the clinical translation of this approach of combining a T cell activation platform with costimulation.
- viagenpumatucel-L (HS-110) / Heat Biologics
A Novel TNFRSF25 Agonist, PTX35, Synergizes with Gp96-Ig/OX40L-Ig to Enhance Effector and Memory Anti-Tumor CD8+ T Cell Responses and Delay Tumor Growth (Prince George's Exhibition Halls AB) - Oct 2, 2019 - Abstract #SITC2019SITC_855;
These results strongly suggest that mPTX35 synergizes with mHS110 and mHS130 to amplify activated tumor-specific CD8+ T cells, program a strong memory response, and allow for tumor regression. The combinations of these three treatments in the clinic may translate into an efficacious approach to treating human cancers.
- viagenpumatucel-L (HS-110) / Heat Biologics, Opdivo (nivolumab) / Ono Pharma, BMS
Treating advanced non-small lung cancer (NSCLC) patients after checkpoint inhibitor treatment failure with a novel combination of Viagenpumatucel-L (HS-110) plus nivolumab (Prince George's Exhibition Halls AB) - Oct 2, 2019 - Abstract #SITC2019SITC_772;
Patients continue to be enrolled into this cohort. Data suggest that re-challenging the immune system with nivolumab and HS-110 after CPI treatment failure restores responsiveness and clinical benefit for some patients.
- | viagenpumatucel-L (HS-110) / NightHawk Biosci
Enrollment closed, Combination therapy, PD(L)-1 Biomarker: DURGA: A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov) - Aug 8, 2019
P1b/2, N=121, Active, not recruiting, Sponsor: Heat Biologics
Data suggest that re-challenging the immune system with nivolumab and HS-110 after CPI treatment failure restores responsiveness and clinical benefit for some patients. Recruiting --> Active, not recruiting
- ||| viagenpumatucel-L (HS-110) / NightHawk Biosci
Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Metastases: A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov) - Feb 22, 2019
P2, N=66, Completed, Sponsor: Heat Biologics
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=123 --> 66 | Trial completion date: Sep 2018 --> Apr 2018 | Trial primary completion date: Sep 2017 --> Dec 2017
- | viagenpumatucel-L (HS-110) / NightHawk Biosci
Trial completion date, Trial primary completion date, Combination therapy, PD(L)-1 Biomarker: DURGA: A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov) - Nov 13, 2018
P1b/2, N=120, Recruiting, Sponsor: Heat Biologics
Active, not recruiting --> Completed | N=123 --> 66 | Trial completion date: Sep 2018 --> Apr 2018 | Trial primary completion date: Sep 2017 --> Dec 2017 Trial completion date: Mar 2019 --> Dec 2021 | Trial primary completion date: Dec 2018 --> Dec 2019
- || viagenpumatucel-L (HS-110) / NightHawk Biosci
Trial completion date, Combination therapy, PD(L)-1 Biomarker: DURGA: A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov) - Mar 3, 2018
P1b/2, N=120, Recruiting, Sponsor: Heat Biologics
Trial completion date: Mar 2019 --> Dec 2021 | Trial primary completion date: Dec 2018 --> Dec 2019 Trial completion date: Dec 2018 --> Mar 2019
- ||| viagenpumatucel-L (HS-110) / NightHawk Biosci
Enrollment change, Trial primary completion date, Combination therapy, PD(L)-1 Biomarker: DURGA: A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jan 18, 2018
P1b/2, N=120, Recruiting, Sponsor: Heat Biologics
Trial completion date: Dec 2018 --> Mar 2019 N=100 --> 120 | Trial primary completion date: Mar 2018 --> Dec 2018
- || viagenpumatucel-L (HS-110) / NightHawk Biosci
Trial primary completion date, Combination therapy, Metastases: A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov) - Apr 24, 2017
P2, N=123, Active, not recruiting, Sponsor: Heat Biologics
N=100 --> 120 | Trial primary completion date: Mar 2018 --> Dec 2018 Trial primary completion date: Jun 2017 --> Sep 2017
- |||| viagenpumatucel-L (HS-110) / NightHawk Biosci
Enrollment open, Combination therapy, PD(L)-1 Biomarker: DURGA: A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov) - Sep 15, 2016
P1b/2, N=100, Recruiting, Sponsor: Heat Biologics
Trial primary completion date: Jun 2017 --> Sep 2017 Active, not recruiting --> Recruiting
- viagenpumatucel-L (HS-110) / NightHawk Biosci
Phase classification, Combination therapy, PD(L)-1 Biomarker: DURGA: A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov) - Sep 2, 2016
P1b/2, N=8, Active, not recruiting, Sponsor: Heat Biologics
Active, not recruiting --> Recruiting Phase classification: P1/2 --> P1b/2
- viagenpumatucel-L (HS-110) / NightHawk Biosci
Enrollment closed, Enrollment change, Combination therapy, PD(L)-1 Biomarker: DURGA: A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov) - Mar 18, 2016
P1/2, N=8, Active, not recruiting, Sponsor: Heat Biologics
Phase classification: P1/2 --> P1b/2 Recruiting --> Active, not recruiting | N=100 --> 8
- ||| viagenpumatucel-L (HS-110) / NightHawk Biosci
Phase classification, Enrollment change, Combination therapy, PD(L)-1 Biomarker: DURGA: A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov) - Dec 31, 2015
P1/2, N=100, Recruiting, Sponsor: Heat Biologics
Recruiting --> Active, not recruiting | N=100 --> 8 Phase classification: P1 --> P1/2 | N=18 --> 100
- viagenpumatucel-L (HS-110) / NightHawk Biosci
Enrollment change, Combination therapy, PD(L)-1 Biomarker: DURGA: A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov) - Sep 2, 2015
P1, N=18, Recruiting, Sponsor: Heat Biologics
Phase classification: P1 --> P1/2 | N=18 --> 100 N=27 --> 18
- ||| viagenpumatucel-L (HS-110) / NightHawk Biosci
Enrollment closed, Combination therapy, Metastases: A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov) - Sep 2, 2015
P2, N=123, Active, not recruiting, Sponsor: Heat Biologics
N=27 --> 18 Recruiting --> Active, not recruiting
- | viagenpumatucel-L (HS-110) / NightHawk Biosci
New P1 trial, Combination therapy, PD(L)-1 Biomarker: DURGA: A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov) - May 8, 2015
P1, N=27, Recruiting, Sponsor: Heat Biologics
- gp96-Ig vaccine / Sylvester Comprehensive Cancer Center, viagenpumatucel-L (HS-110) / NightHawk Biosci
Enrollment change, Trial withdrawal, Metastases: Combination of gp96-Ig Vaccine, Theophylline and Oxygen for the Treatment of Patients With Advanced, Relapsed or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov) - Nov 17, 2014
P1, N=0, Withdrawn, Sponsor: Eckhard Podack
Recruiting --> Active, not recruiting N=36 --> 0 | Not yet recruiting --> Withdrawn
- gp96-Ig vaccine / Sylvester Comprehensive Cancer Center, viagenpumatucel-L (HS-110) / NightHawk Biosci
Trial initiation date, Metastases: Combination of gp96-Ig Vaccine, Theophylline and Oxygen for the Treatment of Patients With Advanced, Relapsed or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov) - Oct 24, 2014
P1, N=36, Not yet recruiting, Sponsor: Eckhard Podack
N=36 --> 0 | Not yet recruiting --> Withdrawn Initiation date: Sep 2014 --> Dec 2014
- gp96-Ig vaccine / Sylvester Comprehensive Cancer Center, viagenpumatucel-L (HS-110) / NightHawk Biosci
Trial initiation date, Metastases: Combination of gp96-Ig Vaccine, Theophylline and Oxygen for the Treatment of Patients With Advanced, Relapsed or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov) - Aug 25, 2014
P1, N=36, Not yet recruiting, Sponsor: University of Miami
Initiation date: Sep 2014 --> Dec 2014 Initiation date: May 2014 --> Sep 2014
- |||| viagenpumatucel-L (HS-110) / NightHawk Biosci
Enrollment open, Combination therapy, Metastases: A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov) - Aug 7, 2014
P2, N=123, Recruiting, Sponsor: Heat Biologics
Initiation date: May 2014 --> Sep 2014 Not yet recruiting --> Recruiting
- ||||| viagenpumatucel-L (HS-110) / NightHawk Biosci
New P2 trial, Combination therapy, Metastases: A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov) - Apr 15, 2014
P2, N=123, Not yet recruiting, Sponsor: Heat Biologics
- gp96-Ig vaccine / Sylvester Comprehensive Cancer Center, viagenpumatucel-L (HS-110) / NightHawk Biosci
Trial initiation date, Metastases: Combination of gp96-Ig Vaccine, Theophylline and Oxygen for the Treatment of Patients With Advanced, Relapsed or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov) - Feb 27, 2014
P1, N=36, Not yet recruiting, Sponsor: University of Miami Sylvester Comprehensive Cancer Center
Not yet recruiting --> Recruiting Initiation date: Apr 2013 --> May 2014
- viagenpumatucel-L (HS-110) / NightHawk Biosci
Trial withdrawal, Combination therapy, Metastases: Immune Response and Safety of HS110 Vaccine in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov) - Nov 19, 2013
P2a, N=0, Withdrawn, Sponsor: Heat Biologics
Initiation date: Apr 2013 --> May 2014 Active, not recruiting --> Withdrawn
- viagenpumatucel-L (HS-110) / NightHawk Biosci
Enrollment change, Combination therapy, Metastases: Immune Response and Safety of HS110 Vaccine in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov) - Nov 19, 2013
P2a, N=0, Withdrawn, Sponsor: Heat Biologics
Active, not recruiting --> Withdrawn N=75 --> 0
- gp96-Ig vaccine / Sylvester Comprehensive Cancer Center, viagenpumatucel-L (HS-110) / NightHawk Biosci
New P1 trial, Metastases: Combination of gp96-Ig Vaccine, Theophylline and Oxygen for the Treatment of Patients With Advanced, Relapsed or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov) - Feb 24, 2013
P1, N=36, Not yet recruiting, Sponsor: University of Miami Sylvester Comprehensive Cancer Center
- gp96-Ig vaccine / Sylvester Comprehensive Cancer Center, viagenpumatucel-L (HS-110) / NightHawk Biosci
Enrollment change, Metastases: Vaccine Therapy in Treating Patients With Stage III, Stage IV, or Relapsed Non-Small Cell Lung Cancer Treated With First-Line Chemotherapy (clinicaltrials.gov) - Oct 15, 2012
P1, N=19, Completed, Sponsor: University of Miami Sylvester Comprehensive Cancer Center
N=75 --> 0 N=36 --> 19